Haloxon
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Haloxon
- DrugBank Accession Number
- DB11419
- Background
Not Available
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 415.58
Monoisotopic: 413.9593583 - Chemical Formula
- C14H14Cl3O6P
- Synonyms
- Haloxon
- Haloxona
- Haloxone
- Haloxonum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Haloxon. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Haloxon. Dexmethylphenidate The serum concentration of the active metabolites of Haloxon can be increased when Haloxon is used in combination with Dexmethylphenidate. Diazoxide The serum concentration of Haloxon can be increased when it is combined with Diazoxide. Doxycycline The therapeutic efficacy of Haloxon can be increased when used in combination with Doxycycline. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- Sub Class
- Not Available
- Direct Parent
- Coumarins and derivatives
- Alternative Parents
- 1-benzopyrans / Pyranones and derivatives / Dialkyl phosphates / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organochlorides show 3 more
- Substituents
- 1-benzopyran / Alkyl chloride / Alkyl halide / Alkyl phosphate / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Benzenoid / Benzopyran / Coumarin show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- T8KXA37068
- CAS number
- 321-55-1
- InChI Key
- KULDXINYXFTXMO-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H14Cl3O6P/c1-9-11-3-2-10(8-12(11)22-14(18)13(9)17)23-24(19,20-6-4-15)21-7-5-16/h2-3,8H,4-7H2,1H3
- IUPAC Name
- 3-chloro-4-methyl-2-oxo-2H-chromen-7-yl bis(2-chloroethyl) phosphate
- SMILES
- CC1=C(Cl)C(=O)OC2=C1C=CC(OP(=O)(OCCCl)OCCCl)=C2
References
- General References
- Humphreys DJ, Stodulski JB, Fysh RR, Howie NM: Haloxon poisoning in geese. Vet Rec. 1980 Dec 6;107(23):541. [Article]
- Cook TF: Toxicity of haloxon in sheep. N Z Vet J. 1966 May-Jun;14(5-6):71-2. [Article]
- Benz GW: Anthelmintic activity of haloxon in calves. Am J Vet Res. 1972 Jun;33(6):1273-6. [Article]
- Cook TF: The anthelmintic efficiency of haloxon in horses. N Z Vet J. 1973 May;21(5):82-4. [Article]
- BAKER NF, DOUGLAS JR: ANTHELMINTIC ACTIVITY OF HALOXON IN LAMBS. Am J Vet Res. 1965 May;26:651-3. [Article]
- Beech JA: Field trials with haloxon against Capillaria in laying fowls. Vet Rec. 1967 Feb 4;80(5):195-8. [Article]
- Lyons ET, Drudge JH, Tolliver SC: Haloxon: critical tests of antiparasitic activity in equids. Am J Vet Res. 1981 Jun;42(6):1043-5. [Article]
- Kingsbury PA, Rees TA, Piercy DW: Haloxon as an anthelmintic for dogs and cats. Vet Rec. 1977 Dec 10;101(24):477-9. [Article]
- Rose RJ, Hartley WJ, Baker W: Laryngeal paralysis in Arabian foals associated with oral haloxon administration. Equine Vet J. 1981 Jul;13(3):171-6. [Article]
- Baker NF, Douglas JR, Fisk RA: Anthelmintic activity of haloxon in calves with parasitic gastroenteritis. Am J Vet Res. 1969 Dec;30(12):2233-5. [Article]
- External Links
- ChemSpider
- 9082
- ChEMBL
- CHEMBL1897362
- ZINC
- ZINC000002040826
- Wikipedia
- Haloxon
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0206 mg/mL ALOGPS logP 3.4 ALOGPS logP 3.87 Chemaxon logS -4.3 ALOGPS pKa (Strongest Basic) -7.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 71.06 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 91.13 m3·mol-1 Chemaxon Polarizability 37.1 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0ik9-0007900000-8175239dd8c02d656b1c Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0089-9350100000-7f4f75acc3665456bbe3 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-7faa0e431917d8ee8432 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0089-9453000000-d15f510113040b346a00 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00ym-1297000000-39066ccda7caa4e070ce Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0089-9150000000-554dc6fc787eba42bf9b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 176.06255 predictedDeepCCS 1.0 (2019) [M+H]+ 178.42097 predictedDeepCCS 1.0 (2019) [M+Na]+ 184.51411 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:37 / Updated at February 21, 2021 18:53